Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice.
暂无分享,去创建一个
B. Cortet | J. Paccou | M. Mignot | N. Taisne | I. Legroux
[1] F. Hsiao,et al. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database , 2016, Osteoporosis International.
[2] P. Vestergaard,et al. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study , 2015, Archives of Osteoporosis.
[3] K. Kostev,et al. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider , 2014, Osteoporosis International.
[4] R. Burge,et al. Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study , 2013, Journal of osteoporosis.
[5] P. Hadji,et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide , 2010, Current medical research and opinion.
[6] J. Adachi,et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. , 2007, Clinical therapeutics.
[7] J. Cramer,et al. Non-compliance: the Achilles' heel of anti-fracture efficacy , 2007, Osteoporosis International.
[8] Jacques P. Brown,et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database , 2003, Osteoporosis International.